MedTrace Logo

Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

NCT03297684 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-02-18

No results posted yet for this study

Summary

To assess the biomarker profile in diabetic macular edema patients in response to intravitreal aflibercept injection. Patients with diabetic macular edema who meet study requirements will receive monthly intravitreal injections of aflibercept as approved by FDA for a period of 6 months. A small quantity of fluid will be removed from the vitreous at each injection for laboratory evaluation of biomarkers present before, during and after treatment with aflibercept.

Conditions

Interventions

DRUG

Aflibercept Injection [Eylea]

Intravitreal injection aflibercept

Sponsors & Collaborators

  • Advanced Eye Research Associates

    lead INDUSTRY

Principal Investigators

  • Mary M Chatterton, MBA, JD · Advanced Eye Research Associates

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-11
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03297684 on ClinicalTrials.gov